a16z Live

a16z Bio + Health #6: AI for Biologics With Mark DePristo and Peyton Greenside

Mar 18, 2021

51:15

Creator website

Highlights

AI Chapters

Episode notes

The Parashooting Analyse

01:57

Latent Space, a Low Dimensional Representation of a Molecular

03:36

Isrit, You're Describing the Intrinsic Trade Offs

03:21

Introduction

5min

Big Hat - How Do We Make Better?

2min

The Key Driver of Biologics?

3min

Monoconal Antibody Design Challenge

3min

Antibody Engineering

4min

Do You Think Analosy Is Very Good?

2min

How to Find a Place to Live in Multi Dimensional Space?

3min

Isrit, You're Describing the Intrinsic Trade Offs

3min

The Parashooting Analyse

2min

10.

The Multi-Matrix Relationship in Drug Development

3min

11.

The Challenge of Building a Culture in Machine Learning

3min

12.

Latent Space, a Low Dimensional Representation of a Molecular

4min

13.

Optimization of Antibodies Using a Modular Platform

4min

14.

Is It a Monoconal Antibody?

4min

15.

Cancer Therapeutics - The Challenge Is Not to Discover New Targets

5min

16.

The Big Hat Operator

1min

On this episode of the a16z Bio Clubhouse Show "It's Time to Heal", a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande talk to guests Peyton Greenside and Mark DePristo of BigHat Biosciences. The conversation covers the growing role of artificial intelligence and machine learning in drug development and specifically in biologics and protein therapeutics.